Skip to main content
PMC home page
International Journal of Hypertension logoLink to International Journal of Hypertension
. 2012 Sep 3;2012:132598. doi: 10.1155/2012/132598

Erratum to “Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities”

Daniel Arthur B Kasal 1,*, Ernesto L Schiffrin 2
PMCID: PMC3439976

The following corrections should be considered.

  1. In the text on page 3, replace the number of reference [26] by [25].

  2. In the text on page 3, replace the number of reference [27] by [26].

  3. In the text on page 3, replace the number of reference [28] by [27].

  4. In the text on page 3, replace the number of reference [29] by [28].

  5. In the text on page 3, replace the number of reference [30] by [29].

  6. In the text on page 3, replace the number of reference [31] by [30].

  7. In the text on page 3, replace the number of reference [32] by [31].

  8. In the text on page 3, replace the number of reference [33] by [32].

  9. In the text on page 3, replace the number of reference [34] by [33].

  10. In the text on page 3, replace the number of reference [35] by [34].

  11. In the text on page 3, replace the number of reference [36] by [35].

  12. In the text on page 3, replace the number of reference [37] by [36].

  13. In the text on page 4, replace the number of reference [25] by [37].

  14. In the legend of Figure 1, replace the number of reference [25] by [37].

  15. Please consider the following corrected reference list for paper.

References

  • 1.Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. The Lancet. 2008;371(9623):1513–1518. doi: 10.1016/S0140-6736(08)60655-8. [DOI] [PubMed] [Google Scholar]
  • 2.Brown LM. Essential hypertension. National Medical Association. 1929;21(1):1–4. [PMC free article] [PubMed] [Google Scholar]
  • 3.Londres G, editor. Hipertensão Arterial. Vol. 235. Rio de Janeiro, Brazil: Livraria Agir Editora; 1945. [Google Scholar]
  • 4.Tigerstedt R, Bergman PG. Niere und kerislauf. Skandinavisches Archiv für Physiologie. 1898;8:223–271. [Google Scholar]
  • 5.White FN, Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron. 1964;204:93–102. doi: 10.1159/000179322. [DOI] [PubMed] [Google Scholar]
  • 6.Rodríguez-Iturbe B, Pons H, Quiroz Y, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney International. 2001;59(6):2222–2232. doi: 10.1046/j.1523-1755.2001.00737.x. [DOI] [PubMed] [Google Scholar]
  • 7.Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Current Opinion in Nephrology and Hypertension. 2003;12(2):181–187. doi: 10.1097/00041552-200303000-00009. [DOI] [PubMed] [Google Scholar]
  • 8.de Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(10):2106–2113. doi: 10.1161/01.ATV.0000181743.28028.57. [DOI] [PubMed] [Google Scholar]
  • 9.Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124(12):1370–1381. doi: 10.1161/CIRCULATIONAHA.111.034470. [DOI] [PubMed] [Google Scholar]
  • 10.Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 2003;42(1):31–38. doi: 10.1161/01.HYP.0000075082.06183.4E. [DOI] [PubMed] [Google Scholar]
  • 11.Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. Journal of Experimental Medicine. 2007;204(10):2449–2460. doi: 10.1084/jem.20070657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Nataraj C, Oliverio MI, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. Journal of Clinical Investigation. 1999;104(12):1693–1701. doi: 10.1172/JCI7451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Jurewicz M, McDermott DH, Sechler JM, et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. Journal of the American Society of Nephrology. 2007;18(4):1093–1102. doi: 10.1681/ASN.2006070707. [DOI] [PubMed] [Google Scholar]
  • 14.Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin II. American Journal of Physiology. 2009;296(2):R208–R216. doi: 10.1152/ajpregu.90521.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Marvar PJ, Thabet SR, Guzik TJ, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circulation Research. 2010;107(2):263–270. doi: 10.1161/CIRCRESAHA.110.217299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Fiebeler A, Schmidt F, Müller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-induced cardiac injury. Hypertension. 2001;37(2):787–793. doi: 10.1161/01.hyp.37.2.787. [DOI] [PubMed] [Google Scholar]
  • 17.Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology. 2002;283(5):H1802–H1810. doi: 10.1152/ajpheart.01096.2001. [DOI] [PubMed] [Google Scholar]
  • 18.Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Canadian Journal of Physiology and Pharmacology. 2005;83(11):999–1006. doi: 10.1139/y05-068. [DOI] [PubMed] [Google Scholar]
  • 19.Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40(4):504–510. doi: 10.1161/01.hyp.0000034738.79310.06. [DOI] [PubMed] [Google Scholar]
  • 20.Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circulation Research. 2005;96(6):643–650. doi: 10.1161/01.RES.0000159937.05502.d1. [DOI] [PubMed] [Google Scholar]
  • 21.Rickard AJ, Young MJ. Corticosteroid receptors, macrophages and cardiovascular disease. Journal of Molecular Endocrinology. 2009;42(6):449–459. doi: 10.1677/JME-08-0144. [DOI] [PubMed] [Google Scholar]
  • 22.Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. Journal of Hypertension. 2009;27(11):2192–2200. doi: 10.1097/HJH.0b013e328330a963. [DOI] [PubMed] [Google Scholar]
  • 23.Wang XL, Rainwater DL, VandeBerg JF, Mitchell BD, Mahaney MC. Genetic contributions to plasma total antioxidant activity. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(7):1190–1195. doi: 10.1161/hq0701.092146. [DOI] [PubMed] [Google Scholar]
  • 24.Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42(6):1075–1081. doi: 10.1161/01.HYP.0000100443.09293.4F. [DOI] [PubMed] [Google Scholar]
  • 25.Sedeek M, Hébert RL, Kennedy CR, Burns KD, Touyz RM. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Current Opinion in Nephrology and Hypertension. 2009;18(2):122–127. doi: 10.1097/MNH.0b013e32832923c3. [DOI] [PubMed] [Google Scholar]
  • 26.Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Experimental and Molecular Medicine. 2004;36(1):65–70. doi: 10.1038/emm.2004.9. [DOI] [PubMed] [Google Scholar]
  • 27.Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51(2):161–167. doi: 10.1161/HYPERTENSIONAHA.107.095489. [DOI] [PubMed] [Google Scholar]
  • 28.Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension. 2004;44(2):195–202. doi: 10.1161/01.HYP.0000132883.20764.12. [DOI] [PubMed] [Google Scholar]
  • 29.Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. Journal of Allergy and Clinical Immunology. 2009;123(4):735–746. doi: 10.1016/j.jaci.2009.02.030. [DOI] [PubMed] [Google Scholar]
  • 30.Hall BM, Jelbart ME, Gurley KE, Dorsch SE. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. Journal of Experimental Medicine. 1985;162(5):1683–1694. doi: 10.1084/jem.162.5.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Powell BR, Buist NRM, Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. Journal of Pediatrics. 1982;100(5):731–737. doi: 10.1016/s0022-3476(82)80573-8. [DOI] [PubMed] [Google Scholar]
  • 32.Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nature Clinical Practice Rheumatology. 2007;3(11):619–626. doi: 10.1038/ncprheum0624. [DOI] [PubMed] [Google Scholar]
  • 33.Rodriguez-Galan MC, Bream JH, Farr A, Young HA. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression. Journal of Immunology. 2005;174(5):2796–2804. doi: 10.4049/jimmunol.174.5.2796. [DOI] [PubMed] [Google Scholar]
  • 34.Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nature Immunology. 2007;8(12):1353–1362. doi: 10.1038/ni1536. [DOI] [PubMed] [Google Scholar]
  • 35.Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nature Reviews Immunology. 2007;7(11):875–888. doi: 10.1038/nri2189. [DOI] [PubMed] [Google Scholar]
  • 36.Garin MI, Chu NC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2007;109(5):2058–2065. doi: 10.1182/blood-2006-04-016451. [DOI] [PubMed] [Google Scholar]
  • 37.Barhoumi T, Kasal DA, Li MW, et al. T Regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57(3):469–476. doi: 10.1161/HYPERTENSIONAHA.110.162941. [DOI] [PubMed] [Google Scholar]
  • 38.Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59(2):324–330. doi: 10.1161/HYPERTENSIONAHA.111.181123. [DOI] [PubMed] [Google Scholar]
  • 39.Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Gender-specific associations between insulin resistance, hypertension, and markers of inflammation among adult Saudis with and without diabetes mellitus type 2. Advances in Medical Sciences. 2010;55(2):179–185. doi: 10.2478/v10039-010-0052-1. [DOI] [PubMed] [Google Scholar]
  • 40.Cheung BMY, Ong KL, Tso AWK, et al. C-reactive protein as a predictor of hypertension in the Hong Kong cardiovascular risk factor prevalence study (CRISPS) cohort. Journal of Human Hypertension. 2011;25(2):108–116. doi: 10.1038/jhh.2010.125. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Hypertension are provided here courtesy of Wiley

RESOURCES